{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:29:36Z","timestamp":1726468176667},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.clinthera.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T02:32:06Z","timestamp":1380853926000},"page":"1842-1848","source":"Crossref","is-referenced-by-count":7,"title":["Setipiprant, a Selective Oral Antagonist of Human CRTH2: Relative Bioavailability of a Capsule and a Tablet Formulation in Healthy Female and Male Subjects"],"prefix":"10.1016","volume":"35","clinical-trial-number":[{"clinical-trial-number":"nct01877629","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Daniela","family":"Baldoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Theodor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.09.003_bib1","first-page":"421","article-title":"New drugs for asthma","volume":"4","author":"Barnes","year":"2004","journal-title":"Discov Med"},{"issue":"6760 Suppl","key":"10.1016\/j.clinthera.2013.09.003_bib2","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1038\/35037000","article-title":"The epidemic of allergy and asthma","volume":"402","author":"Holgate","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2013.09.003_bib3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bmcl.2012.12.050","article-title":"Evolution of novel tricyclic CRTH2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold","volume":"23","author":"Valdenaire","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2013.09.003_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.molmed.2006.02.005","article-title":"Emerging roles of DP and CRTH2 in allergic inflammation","volume":"12","author":"Kostenis","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clinthera.2013.09.003_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2567.2007.02606.x","article-title":"A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes","volume":"121","author":"Vinall","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.clinthera.2013.09.003_bib6","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1067\/mai.2001.119919","article-title":"Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP","volume":"108","author":"Gervais","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.09.003_bib7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.bbrc.2004.02.151","article-title":"Effects of prostaglandin D2 on helper t cell functions","volume":"316","author":"Tanaka","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2013.09.003_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2249.2008.03871.x","article-title":"Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells","volume":"156","author":"Xue","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinthera.2013.09.003_bib9","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.4049\/jimmunol.175.10.6531","article-title":"Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells","volume":"175","author":"Xue","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2013.09.003_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1365-2567.2006.02440.x","article-title":"A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants","volume":"119","author":"Gyles","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.clinthera.2013.09.003_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.09.003_bib12","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1038\/sj.bjp.0707488","article-title":"The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses","volume":"153","author":"Pettipher","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.09.003_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrd2266","article-title":"Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases","volume":"6","author":"Pettipher","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2013.09.003_bib14","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/eji.200535672","article-title":"Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase","volume":"36","author":"Schratl","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clinthera.2013.09.003_bib15","unstructured":"Fretz H, Valdenaire A, Pothier J, et al. Discovery of ACT-129968, a potent, selective, and oral CRTH2 receptor antagonist for the treatment of allergic diseases. Abstract presented at: 244th ACS National Meeting; August 19\u201323, 2012; Philadelphia, Pa"},{"key":"10.1016\/j.clinthera.2013.09.003_bib16","unstructured":"Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist ACT-CRTH2 in healthy subjects. Abstract presented at: 38th Annual Meeting American College of Clinical Pharmacology; September 13\u201315, 2009; San Antonio, Tex"},{"key":"10.1016\/j.clinthera.2013.09.003_bib17","doi-asserted-by":"crossref","unstructured":"Diamant Z, Singh D, O'Connor BJ, et al. Effect of multiple-dose setipiprant, a selective oral CRTH2 antagonist, on allergen-induced airway responses in allergic asthmatic patients. Abstract presented at: American Thoracic Society International Conference; May 18\u201323, 2012; San Francisco, Calif","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A3957"},{"key":"10.1016\/j.clinthera.2013.09.003_bib18","unstructured":"Clinical trial identifiers NCT01225315, NCT01241214, and NCT01484119. http:\/\/clinicaltrials.gov. Accessed September 1, 2013."},{"key":"10.1016\/j.clinthera.2013.09.003_bib19","unstructured":"EMA. Guideline on validation of bioanalytical methods. November 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf. Accessed April 1, 2012."},{"key":"10.1016\/j.clinthera.2013.09.003_bib20","unstructured":"FDA. Guidance for industry bioanalytical method validation. May 2001. http:\/\/wwwfdagov\/downloads\/Drugs\/\/Guidances\/ucm070107pdf. Accessed April 1, 2012."},{"key":"10.1016\/j.clinthera.2013.09.003_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1081\/BIP-100101013","article-title":"Why are pharmacokinetic data summarized by arithmetic means?","volume":"10","author":"Julious","year":"2000","journal-title":"J Biopharm Stat"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813009508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813009508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T21:36:18Z","timestamp":1646688978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813009508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0149291813009508"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.09.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}